ETFs positioned on Novartis AG

Name Weight AuM 1st Jan change Investor Rating
10.40% 121 M€ -.--% -
5.57% 20 M€ +16.75% -
3.79% 2 M€ -25.75%
2.70% 4 M€ -.--% -
2.55% 6 M€ -.--%
2.53% 6 M€ -.--% -
2.00% 3 M€ +11.67% -
1.50% 33 M€ +9.38% -
1.44% 29 M€ +8.37% -
1.43% 2 M€ +9.19% -
1.43% 2 M€ -.--% -
1.41% 177 M€ +10.92%
1.15% 10 M€ -3.35% -
1.00% 8 M€ +6.29% -
0.98% 7 M€ +0.11% -
0.80% 33,076 M€ +14.10% -
0.74% 1,005 M€ +10.43%
0.71% 5 M€ -.--% -
0.53% 284 M€ -.--%
0.51% 23 M€ -.--% -
0.51% 786 M€ -.--%
Logo Novartis AG
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows: - oncology (29.9%); - immunology (17.2%); - cardiovascular, renal and metabolic diseases (14.1%); - neuroscience (8.9%). The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products. At the end of 2023, Novartis AG had 33 production sites worldwide. Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).
Employees
76,057
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
surperformance-ratings-light-chart NOVARTIS-AGMore Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
21
Last Close Price
102.79USD
Average target price
115.73USD
Spread / Average Target
+12.59%
Consensus

Quarterly revenue - Rate of surprise